Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Poster Display Session

248P - The effect of progesterone on ALA-based PDT efficacy in uterine sarcoma cells

Date

22 Nov 2020

Session

e-Poster Display Session

Topics

Tumour Site

Sarcoma

Presenters

Ellie Chu

Authors

E.S.M. Chu1, W.K. Wu1, Z. Huang2

Author affiliations

  • 1 School Of Medical And Health Sciences, TWC-Tung Wah College:King's Park Campus, 852 - Kowloon/HK
  • 2 Moe Key Laboratory Of Photonics Science And Technology For Medicine, Fujian Normal University, Fuzhou, China, Fuzhou/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 248P

Background

Photodynamic Therapy (PDT) is an FDA approved cancer treatment. Hexyl-ALA, one of the 5-aminolevulinic acid (ALA) derivatives, induces higher protoporphyrin IX (PpIX) accumulation in cancer cells through the disrupted heme pathway. Upon specific light activation with oxygen, reactive oxygen species will be released for cancer cell destruction. Studies also revealed that ALA induced higher PpIX accumulation with hormonal supplement. Uterine sarcoma is a hormonal dependent gynecological cancer. Addition of hormones with ALA-PDT might be a new therapeutic approach.

This study aimed to demonstrate the effect of progesterone on hexyl-ALA-PDT in uterine sarcoma cells; the in-depth mechanism related to heme pathway is yet to be explored.

Methods

The intracellular PpIX generation and the phototoxicity mediated by Hexyl-ALA-PDT with progesterone were determined by flow cytometry and MTT assay respectively in the proposed cells.

Results

The PpIX generation and accumulation induced by hexyl-ALA in the proposed cells were increased in 10% and 30% when supplemented with progesterone and with progesterone and ferrochelatase inhibitor respectively. The progesterone enhanced hexyl-ALA-PDT effect from lethal dose of 20 (LD20) to lethal dose of 60 (LD60) at 2J/cm2.

Conclusions

Progesterone significantly enhanced hexyl-ALA-PDT efficacy in uterine sarcoma cells. Progesterone might enhance the efficacy of Hexyl-ALA-PDT through the modulation of heme biosynthetic pathway; thus in-depth mechanistic studies of hormonal enhancement on Hexyl-ALA-PDT efficacy deserved to be explicit.

Acknowledgement

Hexyl-ALA was kindly provided by Photocure ASA. This study was fully supported by a grant from the Research Grants Council (RGC) of the Hong Kong Special Administrative Region, China (Project no.: UGC/FDS17/M06/19).

Clinical trial identification

Editorial acknowledgement

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.